Keros Therapeutics, Inc.

NASDAQ:KROS

Biotechnology

Healthcare
$12.00 +1.20%

+$0.13 today

Market cap
$235.49M
Beta
0.96
P/E (TTM)
-4.6
EPS (TTM)
-$2.29
52W Low $9.69High $22.55

Volume 0.55M

Average 0.36M

KROS Total Debt

Short-term and long-term borrowings combined.

Keros Therapeutics, Inc.NASDAQ: KROS

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt falls 11.4% from a year ago

Total debt stood at $16.31M at the end of Q1 FY2026, down 11.4% from a year earlier and down 3.4% from the prior quarter. Over 3 fiscal years it compounded at +8.4% a year.

Context

  • Total debt amounted to 5.2% of total assets at the end of Q1 FY2026, up 2.9 pp from a year earlier.
  • Total debt increased in 2 of the last 3 fiscal years.

What to watch

Whether total debt keeps falling in the next quarterly balance sheet after a -11.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$16.31M-3.4% QoQ
Last fiscal yearDec 2025
$16.88M-10.5% YoY
Year agoMar 2025
$18.41M-11.4% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-11.4%——
1 year-10.5%——
3-year CAGR+8.4%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
16.88M USD
Year-over-year change
-10.5%
4-year CAGR
+98.2%

Total Debt vs competitors

How KROS compares with its peers on the latest reported figures

  • KROS's Mar 2026 total debt of $16.31M is the 5th highest of the 10 companies compared; the peer median is $4.42M.
  • Its year-over-year change of -11.4% is the 4th highest of 10, against a peer median of -25.1%.
  • Total debt amounts to 5.2% of total assets for KROS, versus a peer median of 2.3%.
KROS Competitors Peer median
Total Debt for KROS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MLTXMoonLake ImmunotherapeuticsMar 2026$100.8M +33.3%+544.7%25.2%
VSTMVerastem, Inc.Mar 2026$85.48M +11.3%+41.6%37.5%
RGNXREGENXBIO Inc.Mar 2026$71.07M -11.0%+40.1%20.8%
RIGLRigel Pharmaceuticals, Inc.Mar 2026$45.72M -25.1%+8.7%9.1%
KROSKeros Therapeutics, Inc.Mar 2026$16.31M -11.4%+8.4%5.2%
ABSIAbsci CorporationMar 2026$4.42M -50.5%-38.7%2.3%
CTMXCytomX Therapeutics, Inc.Mar 2026$2.86M -65.0%-38.3%0.8%
NAGENiagen Bioscience IncMar 2026$2.58M -26.9%-12.9%2.3%
OLMAOlema Pharmaceuticals, Inc.Mar 2026$956K -16.7%-22.5%0.2%
CRVSCorvus Pharmaceuticals, Inc.Mar 2026$834K -27.7%-28.8%0.3%
Peer median (excluding KROS) $4.42M-25.1%-12.9%2.3%

Competitors are the stored peer set for KROS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents230.04M279.05M331.15M559.93M287.42M
Short-term Investments00000
Net Receivables18.2M841K1.09M4.46M6.37M
Inventory00000
Other Current Assets210K276K1M1.48M2.4M
Total Current Assets251.44M285.77M347.29M588.89M315.43M
Property, Plant & Equipment (Net)2.4M17.57M19.47M23.49M21.14M
Goodwill00000
Intangible Assets00000
Long-term Investments001.21M1.45M1.45M
Tax Assets00000
Other Non-current Assets1.41M3.45M2.05M2.06M0
Total Non-current Assets3.81M21.01M22.73M26.99M22.59M
Total Assets255.25M306.78M370.03M615.89M338.02M
Account Payables3.65M3.34M5.45M4.6M1.97M
Short-term Debt00000
Tax Payables110K50K000
Deferred Revenue00000
Other Current Liabilities2.58M5.56M10.38M10.55M6.09M
Total Current Liabilities11.85M16.55M24.37M27.45M20.41M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities231K12.81M13.44M16.88M14.48M
Total Liabilities12.08M29.36M37.81M44.33M34.89M
Common Stock2K2K3K4K4K
Retained Earnings(123.76M)(228.43M)(381.43M)(568.78M)(481.77M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity243.17M277.42M332.21M571.55M303.13M
Total Debt1.09M13.27M14.44M18.86M16.88M
Net Debt(228.95M)(265.78M)(316.7M)(541.07M)(270.53M)

Keros Therapeutics, Inc.

NASDAQ:KROS

Intrinsic Alpha fair value

Locked

Current Price

$12.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.